

Genzyme

[View the current Genzyme Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/537-Genzyme.html)

(<http://www.bioportfolio.com/biocorporate/537-Genzyme.html>)

Contact Details:

500 Kendall Street

Cambridge

MA

02142

United States of America

Tel: 617 252 7500

Fax: 617 252 7600

Email:

Genzyme is one of the world's leading biotechnology companies. Its more than 9,000 employees work in countries throughout the world and are united by a common goal: to make a major positive impact on the lives of people with debilitating diseases. Since its founding in 1981, Genzyme has grown from a small start-up to a diversified enterprise with 2006 revenues of \$3.2 billion. Over the past two decades Genzyme has introduced a number of breakthrough treatments in several areas of medicine, which have provided hope to patients who previously had no viable treatment options. Genzyme products are helping patients in nearly 90 countries. Today, Genzyme continues to be driven by its commitment to patients. The company is working to develop new medicines, improve its existing therapies, secure approvals for its products around the world, and ensure that patients have access to these treatments. Genzyme, which has its headquarters in Cambridge, Massachusetts, was selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States in 2006 and 2007.

Recent Publications by Genzyme:



- [Centromeric alpha-satellite DNA break in reciprocal translocations.](#)
*In the process of selecting fluorescence in situ hybridization probes to...*10th November, 2009
Genzyme Genetics, Monrovia, CA 91016, USA.- Cytogenet Genome Res. 2009;125(4):329-33. Epub 2009 Oct 27. ([DOI Direct Link](#))
- [Selecting an appropriate method for expressing a recombinant protein.](#)
*Recombinant proteins are important tools for studying biological...*7th November, 2009
Genzyme Corporation, Framingham, Massachusetts, USA.- Methods Enzymol. 2009;463:131-47. ([DOI Direct Link](#))
- [Expanding the biopharmaceutical industry's involvement in fighting neglected diseases.](#)
*The increasingly recognized need for new products for so-called neglected...*6th November, 2009

- Genzyme Corporation in Cambridge, Massachusetts, USA.- Health Aff (Millwood). 2009 Nov-Dec;28(6):1774-7. ([DOI Direct Link](#))
- [Discovery of novel sphingosine kinase 1 inhibitors.](#)
*Sphingosine kinase 1 (SK1) is an important enzyme that regulates the...*6th October, 2009
Drug and Biomaterial R&D, Genzyme Corporation, 153 Second Avenue, Waltham,- Bioorg Med Chem Lett. 2009 Nov 1;19(21):6119-21. Epub 2009 Sep 10. ([DOI Direct Link](#))
 - [\[New approaches to rare diseases knowledge\]](#)
*Primary Myelofibrosis previously also known as Agnogenic Myeloid...*3rd October, 2009
Medical Advisor,- Med Clin (Barc). 2009 Jul 4;133(5):193-5. Epub 2009 May 28. ([DOI Direct Link](#))
 - [American Dietetic Association and the National Kidney Foundation Standards of Practice and Standards of Professional Performance for Registered Dietitians \(generalist, specialty, and advanced\) in nephrology care.](#)
*Intestinal phosphate absorption occurs through both a paracellular...*23rd September, 2009
Genzyme Renal, Hampton Bays, NY, USA.- J Am Diet Assoc. 2009 Sep;109(9):1617-25.e33. ([DOI Direct Link](#))
 - [In vivo characterization of rabbit anti-mouse thymocyte globulin: a surrogate for rabbit anti-human thymocyte globulin.](#)
*BACKGROUND: Polyclonal rabbit anti-human thymocyte globulin...*17th September, 2009
Department of Immunology and Clinical Laboratory Sciences, Biologics R&D,- Transplantation. 2009 Jul 27;88(2):170-9. ([DOI Direct Link](#))
 - [A Pharmacokinetic Study of Plerixafor in Subjects with Varying Degrees of Renal Impairment.](#)
*Plerixafor is a selective antagonist of CXCR4, used for mobilization of...*15th September, 2009
Genzyme Corporation, Cambridge, MA, USA.- Biol Blood Marrow Transplant. 2009 Sep 10. ([DOI Direct Link](#))
 - [Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.](#)
*Alemtuzumab is a humanized monoclonal antibody against CD52, an antigen...*11th September, 2009
Genzyme Corporation, Framingham, MA 01701, USA.- Immunology. 2009 Oct;128(2):260-70. ([DOI Direct Link](#))
 - [Knockdown of human deubiquitinase PSMD14 induces cell cycle arrest and senescence.](#)
*The PSMD14 (POH1, also known as Rpn11/MPR1/S13/CepP1) protein within the...*8th September, 2009
Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA.- Exp Cell Res. 2009 Sep 2. ([DOI Direct Link](#))
 - [Intestinal npt2b plays a major role in phosphate absorption and homeostasis.](#)
*Intestinal phosphate absorption occurs through both a paracellular...*5th September, 2009
Renal and Endocrine Sciences Group, Genzyme Corporation, Framingham,- J Am Soc Nephrol. 2009 Nov;20(11):2348-58. Epub 2009 Sep 3. ([DOI Direct Link](#))
 - [Functional polymers as therapeutic agents: concept to market place.](#)
*Biologically active synthetic polymers have received considerable...*18th August, 2009
Drug and Biomaterials R&D, Genzyme Corporation, 153 Second Avenue,- Adv Drug Deliv Rev. 2009 Nov 12;61(13):1121-30. Epub 2009 Aug 12. ([DOI Direct Link](#))
 - [Lysozyme retention on hydrophobic interaction chromatography predicts resin performance at large scale.](#)
*It is critical that manufacturers understand the impact of resin...*5th August, 2009
Purification Development, Genzyme Corporation, Framingham, MA 01701, USA.- Biotechnol Appl Biochem. 2009 Oct 5;54(3):157-62. ([DOI Direct Link](#))
 - [Biology takes centre stage.](#)
*Traditionally, biomaterials have functioned primarily as implants, with...*13th June, 2009
Genzyme, 153 Second Avenue, Waltham, Massachusetts 02451, USA.- Nat Mater. 2009 Jun;8(6):441-3. ([DOI Direct Link](#))
 - [Epigenetic Modifications: New Therapeutic Targets in Primary Myelofibrosis.](#)
*Primary Myelofibrosis previously also known as Agnogenic Myeloid...*9th June, 2009
Genzyme Genetics, 521 West 57th Street, New York, NY - 10019, USA.- Curr Stem Cell Res Ther.

Press Releases on Genzyme:

BioMarin to Present at the NASDAQ OMX 23rd Investor Program	24th November, 2009	BioMarin Pharmaceutical Inc.	NOVATO, Calif., Nov. 24 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company
Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients	23rd November, 2009	Proteon Therapeutics, Inc.	WALTHAM, Mass., Nov. 23 /PRNewswire/ -- Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing
Inimex Announces Appointment of New CEO	23rd November, 2009	Inimex Pharmaceuticals Inc.	BURNABY, BC, Nov. 23 /PRNewswire/ - Inimex Pharmaceuticals, Inc. announced today that it has appointed Michael J. Abrams, Ph.D as its President and CEO. Abrams brings more than 25 years of drug
Reportlinker Adds Automated and Rapid Microbiological Tests - A Worldwide Market Review	18th November, 2009	Reportlinker	NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Automated and Rapid Microbiological Tests - A Worldwide Market Review
Reportlinker Adds Organ and Tissue Transplantation - A World Market Analysis	17th November, 2009	Reportlinker	NEW YORK, Nov. 17 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Organ and Tissue Transplantation - A World Market Analysis http://www

- [Guru Stocks at 52-Week Low: Genzyme Corp, Apollo Group Inc, Cogent Inc, AMERICAN PUBLIC EDUCATION, INC, Whitne](#)
Guru Focus: Nov 22 2009 5:13PM Matching: genzyme
- [Guru Stocks At 52-Week Low: GENZ, APOL,COGT, APEI, WTNY](#)
Guru Focus: Nov 22 2009 4:49PM Matching: genzyme
- [Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder](#)
Bionity.com: Nov 21 2009 5:27AM Matching: genzyme
- [Genzyme woes continue with two product setbacks](#)
Pharmafocus: Nov 20 2009 10:09AM Matching: genzyme
- [SmarTrend's Candlestick Scanner Detects Possible Bullish Engulfin...](#)
Zibb: Nov 20 2009 9:40PM Matching: genzyme
- [SmarTrend's Candlestick Scanner Detects Possible Bullish Engulfing Pattern for Genzyme \(GENZ\)](#)
TradingMarkets: Nov 20 2009 8:41PM Matching: genzyme
- [Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder](#)
PharmaceuticalProcessing: Nov 20 2009 8:23PM Matching: genzyme
- [FDA finds bits of steel, rubber in Genzyme drugs](#)
Canadian Press: Nov 20 2009 7:13PM Matching: genzyme
- [Is bad-news Genzyme paying CEO too much?](#)
FiercePharma: Nov 20 2009 4:32PM Matching: genzyme
- [Genzyme Announces Results Of Phase 2/3 Trial Of Advanced Phosphate Binder](#)
Medical News Today: Nov 20 2009 4:43PM Matching: genzyme
- [BRIEF-EU agency recommends extending use of Genzyme's Thyrogen](#)
Forbes.com: Nov 20 2009 1:38PM Matching: genzyme
- [Medical News: Genzyme Announces Results Of Phase 2/3 Trial Of Advanced Phosphate Binder](#)
BioFind: Nov 20 2009 12:57PM Matching: genzyme
- [Genzyme's Termeer Got \\$50M in Compensation Over Last 3 Years; Wife Got Trips to Asia on Corporate Jet](#)
BNet: Nov 19 2009 11:54PM Matching: genzyme
- [A Week of Woe for Genzyme, A CPR App for Your iPhone, A Better Treatment for Opioid Dependence, and More Boston-Area Life Sciences News](#)
Xconomy: Nov 19 2009 7:14AM Matching: genzyme
- [This Stock Is a Train Wreck](#)
Motley Fool via MSN Money: Nov 19 2009 8:36PM Matching: genzyme

Genzyme Clinical Trials:



- [Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis \(MPS\) I](#)



Genzyme Patents:

- 7253185- [Amino ceramide-like compounds and therapeutic methods of use](#)
- 7332590- [Molecular characteristics of non-small cell lung cancer](#)
- 7341720- [Targeting of glycoprotein therapeutics](#)
- 7351410- [Treatment of Pompe's disease](#)
- 7351577- [Adeno-associated vector compositions for expression of Factor VIII](#)
- 7371366- [GlcNAc phosphotransferase of the lysosomal targeting pathway](#)
- 7387836- [Aziridine compounds and their use in medical devices](#)
- 7396840- [Chemokine receptor binding heterocyclic compounds](#)
- 7399821- [Alkylated poly\(allylamine\) polymers and methods of use](#)
- 7414065- [Methods to modulate conditions mediated by the CXCR4 receptor](#)
- 7417021- [Biologically active conjugate of a biopolymer and therapeutic agent](#)
- 7318919- [Adenovirus vectors for gene therapy](#)
- 7312324- [Regulatory elements for delivery to the liver](#)
- 7307068- [Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products](#)
- 7259151- [AAV virions with decreased immunoreactivity and uses therefor](#)
- 7261544- [Methods for producing preparations of recombinant AAV virions substantially free of empty capsids](#)
- 7261880- [Methods of treating Syndrome X with aliphatic polyamines](#)
- 7265228- [Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors](#)
- 7267822- [Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation](#)
- 7271237- [Method of drying a material having a cohesive phase](#)
- 7285670- [Synthesis of substituted thiazoline carboxylic acids](#)
- 7285676- [Synthesis of chiral 2-alkyl amino acids](#)
- 7291631- [CXCR4 chemokine receptor binding compounds](#)
- 7294718- [Synthesis of a 4-methylthiazole-4\(S\)-carboxylic acid compound](#)
- 7423135- [.beta.-actin and rpS21 promoters and uses thereof](#)
- 7427396- [AAV vectors for gene delivery to the lung](#)
- 7528247- [Process for preparing purine nucleosides](#)
- 7534613- [Methods of treating parkinson's disease using viral vectors](#)
- 7541024- [Low salt forms of polyallylamine](#)
- 7541466- [Tetrahydroisoquinoline derivatives for treating protein trafficking diseases](#)
- 7550484- [Chemokine receptor binding heterocyclic compounds with enhanced efficacy](#)
- 7563591- [Method for assaying the activity of lysosomal enzymes](#)
- 7576234- [Synthesis of 2-alkyl amino acids](#)
- 7579181- [Purification of adenovirus and AAV](#)
- 7588757- [Methods of treating Parkinson's disease using recombinant adeno-associated virus virions](#)
- 7592417- [Method of drying a material having a cohesive phase](#)
- 7528153- [Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors](#)
- 7527956- [Modified human acid sphingomyelinase having increased activity, and methods for making the same](#)
- 7511131- [Antisense modulation of apolipoprotein B expression](#)
- 7452716- [Expression vectors containing hybrid ubiquitin promoters](#)

- 7455248- [Powder delivery device](#)
- 7456156- [Aryl boronic acids for treating obesity](#)
- 7456220- [Immunodulatory compositions and methods of use thereof](#)
- 7459151- [Phosphate-binding polymers for oral administration](#)
- 7465587- [Diagnostic assay device](#)
- 7485458- [Accessory functions for use in recombinant AAV virion production](#)
- 7491735- [Chemokine receptor binding compounds](#)
- 7498346- [Chemokine receptor binding compounds](#)
- 7501518- [Methods of making 2,6-diaryl piperidine derivatives](#)
- 7598070- [Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,

